Vivos Therapeutics, Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7bfa8a30-d7fc-4d0a-9d6b-7fd2947dab7d/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-19.9M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-016854 |
| FY 2024 | $-11.2M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-001750 |
| FY 2023 | $-17.3M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011755 |
| FY 2022 | $-25.0M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-009765 |
| FY 2021 | $-20.4M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-008452 |
| FY 2020 | $-12.0M | 2020-01-01 – 2020-12-31 | evidence 0001493152-22-008452 |
| FY 2019 | $-10.6M | 2019-01-01 – 2019-12-31 | evidence 0001493152-21-006806 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).